Description     Claims  

EP0185387A   [0011] 
WO0194341A   [0077] 
WO0132651A   [0077] 
WO0047212A   [0077] 
WO9835985A   [0077] 
WO0160814A   [0077] 
WO9722596A   [0077] 
WO9730035A   [0077] 
WO9732856A   [0077] 
WO9813354A   [0077] 
WO9902166A   [0077] 
WO0040529A   [0077] 
WO0041669A   [0077] 
WO0192224A   [0077] 
WO0204434A   [0077] 
WO0208213A   [0077] 

J. Pharm. Sci.   [0039] 
McGraw-Hill Dictionary of Chemical Terms   [0049] 
Stereochemistry of Organic Compounds   [0049] 
J. Med. Chem.   [0077] 
Cancer research   [0077] 
Critical reviews in oncology/haematology   [0077] 
Remington's Pharmaceutical Sciences   [0082] 
Leukemia   [0255] 
Biochemistry   [0255] 
Nat. Genet.   [0255] 
Blood   [0255] 
Genetics   [0255] 
Leukemia   [0255] 
Cancer Cell   [0255] 
Nat Med   [0255] 
CA Cancer J Clin   [0255] 
Nature   [0255] 
Nature   [0255] 
Nature   [0255] 
J Neurosci   [0255] 
Drugs   [0255] 
Leukemia   [0255] 
Hum Mol Genet   [0255] 
Methods   [0255] 
Blood   [0255] 
Nat Rev Cancer   [0255] 
Moz (MYST3, KAT6a) inhibitis senescence via the INK4A-ARF pathway   [0255] 
MOZ regulates B cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development   [0255] 
Leuk Res   [0255] 
Development   [0255] 
Genes Dev   [0255] 
Cell Cycle   [0255] 
Genes Chromosomes Cancer   [0255] 
Mol Cell Biol   [0255]